October 12, 2022
GEXVal Inc. has announced that it held an exhibition at the Japan Healthcare Venture Summit hosted at Pacifico Yokohama from October 12 to 14, 2022 (in conjunction with BIO Japan) and that the company met with Nick Champion, a member of the South Australian parliament (Minister of Trade and Investment, Minister of Housing and Urban Development, and Minister of Planning), reporting on the start of Phase I clinical trials of GXV-001, while also exchanging opinions on strengthening cooperation for business foundations in Australia in the future.
GEXVal established a subsidiary for clinical development in Australia in June 2021, established a partnership with a local clinical trial site, CRO* and ARO**, and initiated Phase I clinical trials in July this year. GEXVal received significant support from the Australian Embassy in Japan and the South Australian authorities. At the meeting, the company expressed its sincere gratitude and exchanged opinions on ideas for further business development in Australia, including exploring new business partners, based on the networks built by the company with various local stakeholders. This meeting was featured by various media outlets in Australia.
Melbourne News Journal
Sunshine Coast QLD News
GEXVal strives for research & development toward devising promising drugs for patients and their family that desperate for better treatment as soon as possible.
For future information, please contact us: firstname.lastname@example.org